Morgan Stanley Cue Biopharma, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 29,452 shares of CUE stock, worth $24,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,452

Previous 28,692 2.65%

Holding current value

$24,445

Previous $26,000 23.08%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$0.58 - $0.86 $440 - $653	760 Added 2.65%	29,452 $20,000
Q1 2025 May 15, 2025	SELL	$0.91 - $1.75 $0 - $1	-1 Reduced -0.0%	28,692 $26,000
Q4 2024 Feb 14, 2025	SELL	$0.71 - $1.88 $3,549 - $9,398	-4,999 Reduced 14.84%	28,693 $29,000
Q3 2024 May 14, 2025	SELL	$0.45 - $1.08 $39,288 - $94,291	-87,307 Reduced 72.16%	33,692 $25,000
Q3 2024 Nov 14, 2024	SELL	$0.45 - $1.08 $39,288 - $94,291	-87,307 Reduced 72.16%	33,692 $25,000
Q2 2024 May 14, 2025	BUY	$1.24 - $2.18 $114,459 - $201,227	92,306 Added 321.7%	120,999 $150,000
Q2 2024 Oct 17, 2024	SELL	$1.24 - $2.18 $35,807 - $62,951	-28,877 Reduced 19.27%	120,999 $150,000
Q2 2024 Aug 14, 2024	SELL	$1.24 - $2.18 $35,807 - $62,951	-28,877 Reduced 19.27%	120,999 $150,000
Q1 2024 Oct 17, 2024	BUY	$1.77 - $3.09 $51,112 - $89,229	28,877 Added 23.87%	149,876 $283,000
Q1 2024 Aug 16, 2024	SELL	$1.77 - $3.09 $26,249 - $45,824	-14,830 Reduced 9.0%	149,876 $283,000
Q1 2024 May 15, 2024	SELL	$1.77 - $3.09 $26,249 - $45,824	-14,830 Reduced 9.0%	149,876 $283,000
Q4 2023 Aug 16, 2024	BUY	$1.72 - $3.1 $75,176 - $135,491	43,707 Added 36.12%	164,706 $434,000
Q4 2023 Feb 13, 2024	BUY	$1.72 - $3.1 $69,088 - $124,520	40,168 Added 32.25%	164,706 $434,000
Q3 2023 Nov 15, 2023	BUY	$2.23 - $4.69 $41,756 - $87,820	18,725 Added 17.7%	124,538 $286,000
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $21,421 - $33,820	6,888 Added 6.96%	105,813 $386,000
Q1 2023 May 15, 2023	SELL	$2.41 - $3.74 $192,489 - $298,717	-79,871 Reduced 44.67%	98,925 $353,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $182,863 - $302,222	-76,512 Reduced 29.97%	178,796 $509,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $402,011 - $607,523	-180,274 Reduced 41.39%	255,308 $569,000
Q2 2022 Oct 27, 2022	BUY	$2.49 - $5.92 $590,137 - $1.4 Million	237,003 Added 119.35%	435,582 $1.09 Million
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $590,137 - $1.4 Million	237,003 Added 119.35%	435,582 $1.09 Million
Q1 2022 Oct 27, 2022	SELL	$4.41 - $12.28 $1.05 Million - $2.91 Million	-237,003 Reduced 54.41%	198,579 $969,000
Q1 2022 May 13, 2022	BUY	$4.41 - $12.28 $95,961 - $267,212	21,760 Added 12.31%	198,579 $969,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $3.23 Million - $5.31 Million	-297,412 Reduced 62.71%	176,819 $2 Million
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $4.77 Million - $7.26 Million	474,231 New	474,231 $6.91 Million

Others Institutions Holding CUE

# of Institutions

Shares Held

17.7M

Call Options Held

Put Options Held

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $29.4M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account